Objective: To observe the effect of external application of smecta combined with recombinant human epidermal growth factor on the treatment of radiation dermatitis of grade II or above in the perineum caused by radiation therapy of cervical cancer. Methods: Seventy patients with cervical cancer having grade II or higher perirradial radiodermatitis after radiation therapy were randomly divided into an observation group and a control group. The control group was treated with conventional recombinant human epidermal growth factor, the observation group was treated with Smecta on the basis of conventional care, and the dermatitis recovery, average recovery time, and pain degree were compared between the two groups after treatment. Results: The therapeutic effect of the observation group (88.9%) was significant higher than the control group (59.5%), the healing time [(6.54±4.65) d] was shorter than the control group [(10.80±5.60) d], the pain degree was lower than that of the control group, the differences were statistically significant (P<0.05). Conclusion: For perineal dermatitis in patients with cervical cancer due to radiotherapy, the use of smecta (montmorillonite powder) combined with recombinant human epidermal growth factor can effectively improve the therapeutic effect, shorten the healing time, reduce the pain of patients, and the medical is cheap and easy bought.